Job title: Director, Translational Science
Yannick Bulliard joined Immatics, TX in 2016, where he is leading the development of the company’s preclinical cell therapy portfolio. In addition, he oversees the scientific development of ACTallo®, Immatics’ take on off-the-shelf TCR-T therapy. Prior to Immatics, Dr. Bulliard worked at Amgen, CA, where he was responsible for the development of key strategic preclinical assets in Immuno-Oncology. Dr. Bulliard obtained his Ph.D. from the Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland and followed by a postdoctoral fellowship at the Novartis Institute for Biomedical Research (NIBR), MA.